A few weeks ago, there was an online debate among Kenyan influencers over the use of GLP-1 medication for weight loss. The discussion gained traction after one content creator questioned whether people who are not living with obesity should spend money on GLP-1 injections to lose weight, suggesting that exercise and dietary changes could be alternatives.
While others defended her position, her comments also attracted criticism, with some arguing that weight management is not simply a matter of discipline and that people have different medical and physiological circumstances.
Beyond the social media disagreements, however, lies a question that is becoming increasingly difficult to ignore: Who should actually be using these drugs? Are GLP-1 medications appropriate for anyone looking to shed a few kilos, or should their use be guided by specific medical needs?
According to Dr Lyudmila Schukina, a weight-loss specialist at Nairobi Bariatric Centre, GLP-1 medications are recommended for adults living with obesity, or those who are overweight and have weight-related health complications.
Eligibility is assessed individually, taking into account a person’s body mass index (BMI), waist circumference, medical history, general health, and previous attempts at weight management. Generally, patients with a BMI of 30 or above may be considered for treatment, while those with a BMI of 27 or higher may also qualify if they have conditions such as type 2 diabetes, high blood pressure, high cholesterol, or sleep apnea.
‘For somebody who is already at a healthy weight and just wants to lose five kilogrammes to look slimmer, I wouldn’t recommend these injections,’ she says. ‘These are medical treatments, not something to take just because it’s fashionable.’
If you ever want to get pregnant
Lisabel Nabwile, a clinical nutritionist and dietician at AAR Health Care Clinic, Rupaz Fun and Fitness Centre, and Metrocare Clinic, shares this view. ‘For someone who has no underlying health concerns but wants to shed a modest amount of weight, I would say go the nutrition way. Have a meal plan, work on your calorie intake, increase your physical activity and get enough sleep,’ she says.
However, meeting the general eligibility criteria does not automatically mean someone should be prescribed the medication. A qualified professional’s assessment is necessary to establish whether it is appropriate, taking into account their health history and any potential risks.
‘Before prescribing the injections, we check the patient’s weight, BMI, blood pressure, medical history and any medication they are already taking,’ says Dr Schukina. ‘We also do blood tests to check blood sugar, kidney function, and often liver function and cholesterol.’
The doctor also asks about previous pancreatitis, gallbladder problems, stomach conditions and pregnancy plans.
‘The medications should not be used during pregnancy,’ she cautions. ‘We also don’t prescribe them to patients with certain rare thyroid cancer conditions, particularly medullary thyroid cancer or MEN2 (multiple endocrine neoplasia type 2). For patients who have serious problems with stomach emptying or a history of pancreatitis, we have to employ careful consideration.’
To understand why these medications are prescribed for weight management, it helps to first understand what GLP-1 does in the body.
GLP-1, or glucagon-like peptide-1, is a hormone that the body naturally produces to help regulate blood sugar and appetite. Medications that mimic its action were initially developed to treat type 2 diabetes. However, doctors noticed that patients taking them were also losing considerable amounts of weight. Further studies were conducted, leading to the development of certain formulations specifically approved for weight management, including in people who do not have diabetes.
Doesn’t burn fat directly
Today, Dr Schukina says, these medications have become an important part of obesity treatment. However, she explains that the injections do not burn fat directly. Rather, they help people eat less, creating the conditions for weight loss.
‘They help you feel full faster, eat smaller portions, and not think about food as much,’ she says. ‘They also slow down how quickly food leaves the stomach, especially at the beginning of treatment.’
But hunger is not the only reason people eat. Stress, emotions, boredom, and long-established habits can also influence eating behaviour.
‘An injection will not automatically change all that,’ Dr Schukina cautions. ‘Which is why we combine the medical treatments with psychotherapy. This allows us to help our patients understand and work on their eating behaviours as well because these are very important for maintaining the results.’
Proper nutrition and physical activity are other important considerations that Lisabel says should be part of the treatment programme.
‘When your appetite is suppressed by these injections, the quantity of food you take naturally decreases. You may even end up skipping meals, which can make it harder for you to consume enough of the nutrients your body needs,’ she says. ‘This means you can potentially fall short on protein, essential fats, fibre, vitamins, minerals, and fluids.’
Beyond affecting the body’s ability to function properly, a nutrient deficiency could also mean losing muscle alongside fat. Weight loss and healthy weight loss are not necessarily the same thing, so to help preserve muscle, Lisabel recommends following a nutrition plan that provides enough nutrients, particularly protein, alongside regular physical activity.
The types
Beyond their effects on appetite and weight, GLP-1 medications also differ in how they work. Semaglutide, which is sold under brand names such as Ozempic and Wegovy, acts only on one hormone, GLP-1. Tirzepatide, on the other hand, sold as Mounjaro, works on two hormones, GLP-1 and GIP (glucose-dependent insulinotropic polypeptide).
Both semaglutide and tirzepatide are taken as an injection under the skin once a week, in the stomach area, thigh, or upper arm. Semaglutide also comes in tablet form, although not all forms are approved for weight loss in every country.
In terms of effectiveness, Dr Schukina says tirzepatide generally produces greater weight loss than Semaglutide. She cites the SURMOUNT-5 trial, which compared the two medications in adults living with obesity but without diabetes. After 72 weeks, participants taking tirzepatide lost an average of about 20 per cent of their body weight, compared with approximately 14 per cent among those taking semaglutide.
‘But these are averages,’ she says. ‘Some people lose more, some less, depending on how they respond to treatment. And we should also remember that Ozempic and Wegovy both contain semaglutide, but they have different approved uses and doses.’
Treatments are not started at the highest possible dose. Instead, patients begin with a small dose that is gradually increased according to their response and tolerance.
‘With weekly semaglutide for weight loss, we usually start at 0.25 mg, then increase through 0.5 mg, 1mg, 1.7 mg, up to 2.4 mg,’ she says. ‘With Mounjaro, we start at 2.5 mg, then increase to 5 mg, 7.5 mg, 10 mg, 12.5 mg, and up to 15 mg.’
Doses are generally increased no more frequently than every four weeks, says Dr Schukina. Although higher doses can produce greater weight loss, they can also increase the likelihood of side effects.
‘There is therefore no need to rush the process,’ she says. ‘If somebody is doing well, we look at their progress and how they tolerate the medication before changing the dose.’
Some patients begin losing weight within the first few weeks, but meaningful results generally take several months, partly because the dose is increased gradually. And while some patients lose considerable amounts of weight, others lose less, and a small number may not respond particularly well.
‘If the patient is not losing enough weight, we reassess their dosage, eating habits, medical conditions, and whether we need to change the treatment,’ she says.
The cost
The cost of the treatment is another consideration for anyone thinking about using the injections.
Treatment starts at Sh45,000 per month for the initial dose, with the cost increasing as the dosage is gradually raised.
‘People also need to understand that this is not a one-month treatment,’ says Dr Schukina. ‘Most patients will need several months, and some may need it much longer. So we discuss the costs from the beginning. We want patients to understand what they are starting and be able to continue the treatment properly.’
The medication also comes with possible side effects. The most common ones are nausea, vomiting, constipation, diarrhoea, bloating and stomach discomfort. These symptoms are usually worse when patients start treatment or increase their doses, but for many patients, they tend to improve with time.
‘But there can also be more serious problems, like pancreatitis, gallbladder problems or dehydration that affects the kidneys,’ says Dr Schukina. ‘If someone has very strong stomach pain, especially if it goes to the back, or they keep vomiting and cannot drink water, they need medical help immediately. Sudden vision loss or difficulty breathing also needs urgent attention.’
Beyond the possible side effects, the growing popularity of GLP-1 injections has also raised concerns about how people are accessing them.
‘People are getting them from friends, online sellers or people with no medical training, and this worries me a lot,’ says Dr Schukina.
She warns that some products may be counterfeit or improperly stored, while people buying them without medical guidance risk taking the wrong dose or using medication that may not be suitable for their health conditions.
‘People should also never share injection pens, even if they change the needle,’ she says. ‘These are not vitamins. They are prescription medications. Saving money by buying injections from an unknown seller could end up costing you much more in hospital bills.’
When you stop the drugs
Another important consideration is what happens when the medication is stopped. While some people may approach the injections as a short-term intervention- take them for a few months, lose weight and then stop- both experts say it doesn’t always work like that. When the medication is stopped, hunger often comes back. Studies have shown that many patients regain a significant part of the weight they lost. In one study, people regained around two-thirds of their lost weight within a year after stopping use of semaglutide.
‘Losing weight and keeping it off are two different things,’ says the weight-loss specialist. ‘Hormones and metabolism are important, but if we don’t work on behaviour, it becomes much harder to keep the results.’
Lisabel agrees. She particularly cautions against viewing the injections as a quick reset before returning to previous habits.
‘It is possible to retain the results, but it can be quite difficult to do if you’re not doing follow-up reviews and being consistent with your nutritional intake and lifestyle changes. You will have to be very intentional,’ she says.
Ultimately, Lisabel believes the measure of successful weight loss should go beyond the number displayed on the weighing scale.
‘I believe we need to change the way we define successful weight loss. The number on the scale is only one measure. It doesn’t tell the whole story of a person’s health,’ she says.
For Dr Schukina, anyone considering GLP-1 medication should first take a step back and examine why they want to lose weight, how much they hope to lose and what they have already tried. And while the injections can produce significant results, she cautions against viewing them as a solution to every weight-related concern.
‘We see patients who lose weight, their blood pressure improves, their diabetes becomes easier to control, and they feel much better,’ she says. ‘But I don’t want people to think an injection will solve everything.’